Polyethylene glycol 4000

OSLO, Norway, Feb. 15, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) , a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark. The company's gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 51.6 million, compared with NOK 51.7 million in 2022. Operating results (EBIT) amounted to NOK 23.6 million, compared to NOK 44.4 million in 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also included in the EBITDA is a negative contribution of 4.8 MNOK from the Sensidose business. "We are looking back at an eventful and transformative year. With the Sensidose acquisition, we gained a promising position in the market for treatment of Parkinson's Disease, and we renewed and secured new marketing and distribution agreements for several other high selling products, including Eroxon®, a clinically proven treatment of erectile dysfunction. Eroxon® was launched in Norway this week and will soon also be available in Sweden," said Kathrine Gamborg Andreassen, CEO of Navamedic. "Furthermore, in the fourth quarter 2023, we signed a term sheet with the Finnish pharmaceutical corporation Orion Pharma, which we are currently finalising into an agreement for a licensing and supply of Flexilev® and OraFID® in Europe, products that were acquired through Sensidose. In Sweden, Norway and Denmark, we will market and sell these products from our own proven platform," Andreassen added. Revenues in the fourth quarter of 2023 was NOK 125 million, up 8.1 percent from the same period last year. Gross margin was 36.5 per cent, down from 42.9 per cent, and Adjusted EBITDA was NOK 7.9 million, compared with NOK 15.7 million in the fourth quarter of 2022. Category update In the Consumer Health category, Modifast cemented its position with continued strong sales in Sweden, and Absolute Torr gained traction with a 54 per cent growth year-over-year in the fourth quarter. Further growth to be achieved through combination of consumer and pharmacy engagement, sale of unique and profitable products in home markets and out-licensing of own products elsewhere. The Hospital category saw double-digit growth year-over-year across the portfolio of antibiotics and medical nutrition products. It also renewed exclusive rights to Vitaflo's medical nutrition products across the Nordic for five more years. Winning new antibiotic tenders is core in the growth strategy, along with initiatives to expand and secure new marketing authorisations. The Prescription Drugs category had strong growth across various therapeutic areas, with continued high demand for Mysimba for obesity treatment, and strong sales of Imdur, Nitrolingual and Forlax. In this category, Navamedic is now preparing rollout of Flexilev with MyFID® and OraFID® in the Nordic countries and out-licensing in the rest of Europe. Outlook Navamedic sees continued strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company with a 15 per cent EBITDA margin. "We are building on a solid foundation. We will continue to strengthen our existing business by leveraging our highly scalable market access platform. We will explore opportunities for market expansion with own products and increase company value by acquiring and strengthening own products and brands while increasing gross margins through careful management of our product portfolio," Andreassen concluded. Navamedic will present the results for the fourth quarter and full year 2023 at 08.30 today. The presentation will take place at Dronning Eufemias Gate 16 in Oslo, and will be available to follow via webcast at the following link: Representatives from Navamedic's management team, CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation. EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached presentation on slide 23. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. The following files are available for download:

Oct. 21, 2021 05:36 UTC PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales summary (unaudited IFRS consolidated sales) Third Quarter Year To Date 2021 2020 % change 2021 2020 % change €m €m Actual CER1 €m €m Actual CER1 Specialty Care 667.8 580.5 15.0% 15.1% 1,912.3 1,747.6 9.4% 12.5% Consumer Healthcare 59.6 52.8 12.8% 12.2% 165.5 154.0 7.5% 9.8% Total Sales 727.4 633.3 14.9% 14.9% 2,077.7 1,901.6 9.3% 12.3% Highlights – Total sales growth of 12.3% at CER1 in the year to date, or 9.3% as reported, to €2,077.7m. In the third quarter, total sales of €727.4m represented growth of 14.9% at CER1 and as reported – An increase in Specialty Care sales in the year to date of 12.5%1 to €1,912.3m, driven by the growth of Somatuline® (lanreotide), Cabometyx® (cabozantinib), Decapeptyl® (triptorelin) and Dysport® (botulinum toxin type A) – Consumer Healthcare sales growth of 9.8%1 in the year to date to €165.5m, reflecting the performance of Smecta® (diosmectite) and the strong COVID-19 recovery – Strong business-development activity, with agreements in Oncology and Neuroscience – Full-year guidance upgraded: Total sales growth1: greater than +11.0% (prior guidance: greater than +8.0%) Core operating margin2: around 34% (prior guidance: around 32.0%) David Loew, Chief Executive Officer, commented: “We delivered a strong performance in the third quarter, reflecting the implementation of our new strategy and improving levels of commercial execution. Somatuline and Cabometyx growth was particularly encouraging, while strong sales of Dysport continue to underpin confidence in the potential of this important medicine. Despite regulatory delays for palovarotene in FOP, the replenishment of our pipeline gathered pace, with our external-innovation strategy providing an exciting platform for sustainable top-line growth. We continue to maximize our brands, strengthen the pipeline and are driving efficiencies across our business. This strategy, built on our culture and an unrelenting focus on patients, is delivering strong results, giving us the confidence to upgrade this year’s guidance while remaining focused on the long-term Ipsen growth story.” FY 2021 guidance Based on the strong performance in the year to date, the gradual easing of the COVID-19 pandemic and a limited impact from the launch of generic lanreotide in Europe, the Company today upgrades its financial guidance for FY 2021: New guidance Prior guidance Total sales growth3 Greater than 11.0% Greater than 8.0% Core operating margin4 Around 34% Around 32.0% Currency impact Ipsen anticipates an unchanged adverse impact of 2% from currencies on total sales in FY 2021, based on the level of exchange rates at the end of September 2021. Business development Since the publication of the H1 2021 results announcement, Ipsen signed two agreements in line with its external-innovation focus on strengthening the pipeline: METTL3 (Oncology) In October 2021, Ipsen and Accent Therapeutics (Accent) signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program. This collaboration reinforces Ipsen’s expansion into hematological malignancies, with a focus on acute myeloid leukemia. Spherical Nucleic Acids (Neuroscience) In August 2021, Ipsen entered into an exclusive collaboration agreement with Exicure to research, develop, and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington’s disease and Angelman syndrome. Palovarotene In August 2021, Ipsen withdrew the New Drug Application (NDA) for palovarotene in FOP5, after discussions with the U.S. Food and Drug Administration (FDA). This followed ongoing dialogue with the FDA after the acceptance of the NDA for Priority Review, announced in May 2021. During the review and the ongoing dialogue, it was recognized that additional analyses and evaluation of data collected from Ipsen’s Phase III MOVE and FOP program would be required to progress and complete the review process. It was agreed that it would not be possible to complete this within the NDA review cycle. Upon successful completion of the additional data analyses, Ipsen currently anticipates regulatory resubmission in the U.S. in H1 2022. A ‘clock-stop’ was also granted by the European Medicines Agency. Conference call A conference call and webcast for investors and analysts will begin at 2:30pm Paris time today. Participants should dial in to the call early and can register here; a recording will be available on ipsen.com, while the webcast can be accessed here. The event ID is 4312698. Calendar The Company intends to publish its FY 2021 results on 11 February 2022. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2021 (the year to date or YTD 2021) and the three-month period to 30 September 2021 (the third quarter or Q3 2021), compared to nine-month period to 30 September 2020 (YTD 2020) and the three-month period to 30 September 2020 (Q3 2020) respectively, unless stated otherwise. Commentary is based on the performance in YTD 2021, unless stated otherwise. Ipsen Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience; it also has a well-established Consumer Healthcare business. With total sales of over €2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has c.5,700 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Sales by therapeutic area and product Third Quarter Year To Date 2021 2020 % change 2021 2020 % change €m €m Actual CER6 €m €m Actual CER6 Total Specialty Care 667.8 580.5 15.0% 15.1% 1,912.3 1,747.6 9.4% 12.5% Oncology 552.3 479.1 15.3% 15.2% 1,565.4 1,446.5 8.2% 11.0% Somatuline 313.0 272.9 14.7% 15.0% 874.4 835.1 4.7% 8.5% Decapeptyl 110.1 94.5 16.5% 15.0% 332.6 288.0 15.5% 15.9% Cabometyx 91.8 76.8 19.5% 19.2% 258.6 213.6 21.1% 21.6% Onivyde® 35.2 27.5 28.0% 29.2% 93.0 90.0 3.3% 10.4% Other Oncology 2.2 7.4 -70.2% -70.4% 6.7 19.8 -65.9% -66.2% Neuroscience 103.8 87.9 18.1% 19.1% 309.6 258.4 19.8% 25.1% Dysport 102.5 87.4 17.3% 18.2% 305.3 256.9 18.8% 24.0% Rare Diseases 11.7 13.5 -13.5% -13.7% 37.3 42.6 -12.5% -11.3% NutropinAq® 7.5 8.5 -12.6% -13.0% 24.5 27.7 -11.6% -11.9% Increlex® 4.2 5.0 -14.9% -14.7% 12.8 14.9 -14.0% -10.1% Total Consumer Healthcare 59.6 52.8 12.8% 12.2% 165.5 154.0 7.5% 9.8% Smecta 27.9 20.2 38.1% 36.4% 63.5 58.0 9.6% 11.9% Tanakan® 7.3 7.2 1.8% 0.6% 27.9 26.6 5.0% 8.7% Forlax® 8.6 10.2 -16.0% -16.0% 25.8 30.0 -13.9% -12.9% Fortrans/Eziclen® 9.3 7.2 30.1% 29.4% 26.0 19.0 36.8% 40.6% Other Consumer Healthcare 6.5 8.1 -19.4% -18.6% 22.2 20.4 8.7% 10.7% Total Sales 727.4 633.3 14.9% 14.9% 2,077.7 1,901.6 9.3% 12.3% Specialty Care In the year to date, Specialty Care sales amounted to €1,912.3m, an increase of 12.5%7. Oncology and Neuroscience sales increased by 11.0%7 and 25.1%7 to €1,565.4m and €309.6m, respectively, while Rare Disease sales declined by 11.3%7 to €37.3m. Specialty Care comprised 92.0% of total sales (YTD 2020: 91.9%). Oncology Sales of €1,565.4m in the year to date represented growth of 11.0%7 reflecting good performance from Somatuline, Cabometyx and Decapeptyl, driven by continued market-share gains in most markets and a strong Decapeptyl recovery in China. Oncology sales comprised 75.3% of total sales (YTD 2020: 76.1%). Somatuline sales reached €874.4m, an increase of 8.5% 7 , with growth of 9.3% 7 in North America that reflected strong volumes, even with the residual impact of COVID-19 on patient diagnoses and treatments. The performance was also a result of continued market-share gains in most geographies. There was only a limited impact from generic octreotide and no impact of generic lanreotide sales in Europe. Decapeptyl sales of €332.6m reflected growth of 15.9% 7 , mainly driven by China, which significantly recovered from the impacts of COVID-19, along with market-share gains in rest of Asia, France and Spain. Cabometyx sales reached €258.6m, up by 21.6% 7 , driven by a strong volume uptake across most geographies in both renal cell carcinoma and hepatocellular carcinoma. Onivyde (irinotecan liposome injection) sales of €93.0m, growing by 10.4% 7 , were driven by higher sales to Ipsen’s ex-U.S. partner and higher volumes in the U.S. Neuroscience Dysport sales in the year to date reached €305.3m, up by 24.0%7, driven by a strong recovery from the pandemic in most geographies for aesthetics markets, mainly in the Middle East, Turkey and Russia, along with therapeutics markets in North America and Europe. There was also a continued solid aesthetics performance from Ipsen’s partner, Galderma, in most of its markets. Neuroscience sales comprised 14.9% of total sales (YTD 2020: 13.6%). Rare Disease NutropinAq (somatropin) sales in the year to date of €24.5m, a decline of 11.9%7, reflected a slowdown in the market and competitive pressures across Europe. A decline in Increlex (mecasermin) sales of 10.1%7 to €12.8m was a result of lower demand in the U.S., reflecting the ongoing effects of COVID-19. Rare Disease sales comprised 1.8% of total sales (YTD 2020: 2.2%). Consumer Healthcare Sales of €165.5m in the year to date, up by 9.8%7, was a result of the 11.9%7 growth in sales of Smecta to €63.5m that was driven by the COVID-19 recovery in China and Russia. Fortrans/Eziclen (macrogol 4000) sales increased by 40.6%7 to €26.0m, also reflecting the recovery in China. Tanakan (ginkgo biloba extract) sales increased by 8.7%7 to €27.9m, driven by performance and a high level of deliveries in Vietnam. Consumer Healthcare sales comprised 8.0% of total sales (YTD 2020: 8.1%). Sales by geographical area Third Quarter Year To Date 2021 2020 % change 2021 2020 % change €m €m Actual CER8 €m €m Actual CER8 Major Western European Countries 218.3 201.4 8.4% 7.5% 659.1 615.7 7.0% 6.9% France 77.7 73.2 6.2% 6.2% 233.1 220.0 6.0% 6.5% Germany 48.0 52.1 -7.8% -7.8% 150.2 146.1 2.8% 2.8% Italy 31.1 21.8 42.5% 42.5% 96.5 82.9 16.4% 16.4% U.K. 31.3 28.2 11.2% 5.0% 90.0 85.6 5.1% 2.8% Spain 30.1 26.1 15.4% 15.4% 89.2 81.0 10.1% 10.1% Other European Countries 136.6 115.1 18.8% 19.6% 394.2 364.3 8.2% 11.8% Eastern Europe 66.7 50.9 30.9% 31.2% 185.5 157.9 17.4% 23.5% Others Europe 70.0 64.1 9.1% 10.2% 208.8 206.4 1.2% 2.9% North America 246.8 204.5 20.7% 21.7% 649.8 623.3 4.2% 10.6% Rest of the World 125.7 112.4 11.8% 10.6% 374.6 298.2 25.6% 27.6% Asia 62.6 60.0 4.4% 1.8% 188.9 135.7 39.2% 38.7% Other Rest of the World 63.1 52.4 20.4% 20.6% 185.7 162.5 14.3% 18.3% Total Sales 727.4 633.3 14.9% 14.9% 2,077.7 1,901.6 9.3% 12.3% Major Western European countries In the year to date, sales reached €659.1m, an increase of 6.9%8. Major Western European countries comprised 31.7% of total sales (YTD 2020: 32.4%). France: sales of €233.1m, reflecting growth of 6.5% 8 , reflected a solid recovery from the pandemic, with continued market-share gains for Somatuline and Decapeptyl, along with additional Onivyde sales to Ipsen’s ex-U.S. partner. This was offset by the effect of a low diarrhea market impacting the Consumer Healthcare performance. Germany: sales reached €150.2m, up by 2.8% 8 , mainly driven by continued market-share gains for Cabometyx and Somatuline, with no material impact from the launch of generic lanreotide. Italy: sales of €96.5m, up by 16.4% 8 , were mainly a result of a solid Cabometyx uptake and the Somatuline performance. U.K.: sales reached €90.0m, an increase of 2.8% 8 , mainly driven by a strong Somatuline performance, partly offset by lower volumes of Decapeptyl. Spain: sales of €89.2m reflected growth of 10.1% 8 , driven by market-share gains for Somatuline and Decapeptyl. Other European countries In the year to date, sales reached €394.2m, up by 11.8%9, mainly driven by market-share gains and successful launches for Cabometyx, strong Dysport performances in Turkey and Russia, along with good Consumer Healthcare sales in Eastern Europe. Other European countries sales comprised 19.0% of total sales (YTD 2020: 19.2%). North America Sales of €649.8m in the year to date reflected growth of 10.6%9, driven by continued strong Somatuline and Cabometyx demand, despite an overall adverse impact from the pandemic on cancer treatment. Strong Dysport sales reflected good performance in the aesthetics and therapeutics markets after the impact of COVID-19 in 2020. North America sales comprised 31.3% of total sales (YTD 2020: 32.8%). Rest of the World Sales reached €374.6m in the year to date, an increase of 27.6%9, driven by the China recovery that resulted in strong Decapeptyl and Consumer Healthcare sales. This was accompanied by a solid Dysport performance in Latin America and the Middle East, along with good Decapeptyl sales mainly in South Korea and Taiwan. Rest of the World sales comprised 18.0% of total sales (YTD 2020: 15.7%). Forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s 2020 Universal Registration Document, available on ipsen.com. 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 As a ratio of core operating income to total sales. 3 At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 4 As a ratio of core operating income to total sales. 5 Fibrodysplasia ossificans progressiva. 6 At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 7 At CER, which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 8 At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 9 At CER, which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. View source version on businesswire.com: Contacts Investors Craig Marks Vice President, Investor Relations +44 7584 349 193 Adrien Dupin de Saint-Cyr Investor Relations Manager +33 6 64 26 17 49 Media Gwenan White Executive Vice President, Communications and Public Affairs +44 7876 391 429 Fanny Allaire Global Communications Director + 33 6 08 91 92 55 Source: Ipsen View this news release online at: